Video

Q&A With Gerald Smetana, MD, from Beth Israel Deaconess Medical Center: Weighing Benefits of Vorapaxar for Patients

Author(s):

With primary care physicians treating such a broad spectrum of conditions they also have a number of medications they can prescribe to help their patients. While some of these are more beneficial than others it is important to consider which might be more effective for patients.

With primary care physicians treating such a broad spectrum of conditions they also have a number of medications they can prescribe to help their patients. While some of these are more beneficial than others it is important to consider which might be more effective for patients.

Gerald Smetana, MD, from Beth Israel Deaconess Medical Center discussed four medications during the American College of Physicians Internal Medicine Meeting in Boston. One medication discussed, Vorapaxar, has been approved to help patients avoid a second cardiovascular event.

Related Videos
Marcelo Kugelmas, MD | Credit: South Denver Gastroenterology
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
© 2024 MJH Life Sciences

All rights reserved.